University of London

London, England
Department of Neuroscience

Research

Children and adolescents who are cancer patients have only a few treatments specifically designed for their cancer. The lack of development of pediatric cancer drugs forces pediatric oncologists to use adult cancer drugs to treat their young patients. Dr. Cesare Spadoni, who lost his first daughter to cancer, is identifying treatments for the most common pediatric cancers with poorest prognoses. Two of the cancers at the forefront of his efforts are Medulloblastoma and Rhabdomyosarcoma.

Medulloblastoma accounts for 20% of all childhood brain tumors and has high heterogeneity and a tendency to metastasize. Ongoing research has identified 3 synergistic combinations that inhibit several targets found in the cancer and next steps with bioinformatics will identify a lead compound against two targets in vitro and in vivo models of medulloblastoma.

Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma with the aggressive subtype, alveolar rhabdomyosarcoma, resulting from fusion of two genes, PAX3 and FOXO1. In preclinical research, the small molecule drug, volasertib, which inhibits PLK1 enzyme, results in reduced expression of the abnormal fused proteins. Volasertib has already been studied as single agent in Phase I clinical trials in children with leukemia and refractory solid tumors and the recommended Phase 2 dose (RP2D) for children has been defined. The combined treatment of volasertib and chemotherapy vincristine may begin a Phase I clinical trial to treat relapsed or refractory rhabdomyosarcoma patients with and without the gene fusion abnormalities.

With NFCR support, Dr. Spadoni’s efforts have led to this promising therapeutic now being commercialized through the AIM-HI Translational Research Initiative. To learn more, click here.

Bio

Cesare Spadoni holds an MSc in Applied Molecular Biology and a PhD in Neurosciences from UCL, University of London, as well as an MBA from the Central European University, Budapest. He has more than 20 years of experience in the drug development field, in both scientific and commercial roles. He started his career as research scientist in a pharmaceutical company (Eisai, London) and in academia (Institute of Enzymology, Budapest. He held senior positions at AMRI, Aptuit Laurus, ThalesNano and Auxiliis BV. After losing his first daughter to cancer, he founded the aPODD foundation, a London-based charity focused on accelerating pediatric oncology drug development for treating childhood cancer. As chairman and trustee, he is actively involved on a pro-bono basis in drug repurposing projects, advocacy efforts and research collaborations with other childhood cancer charities.

Related Content

Don’t Delay: Skipping One Mammogram Can Significantly Increase Risk of Death from Breast Cancer

One mammogram every two years doesn’t sound so bad – but what happens if a woman skips one? A recent study warns that missing just one mammogram before being diagnosed with cancer significantly increases a woman’s probability of dying from the disease.  The Importance of Mammograms Mammograms allow medical professionals to examine an x-ray of the breast tissue and look for any abnormalities or hints of cancer that other methods may not be able to detect. Having regularly scheduled mammograms presents an opportunity for early diagnosis, which significantly increases the ability to administer successful treatment. As signs and symptoms are often difficult to observe at early stages, mammograms have been the gold standard used for cancer detection and may reduce mortality by up to 40%. Because of this, the United States Preventative Services Task Force recommends that women aged 50-74 undergo a mammography every two years. Alarming Study Results In this ground-breaking study, a research team led by Stephen W. Duffy and Laszlo Tabar analyzed data from nearly 550,000 women with access to mammograms between 1992 and 2016. This data was divided into two groups – women who attended the two of the most recent mammograms before being diagnosed with breast cancer and those who did not.  The team discovered that the group who did not attend the two most recent mammograms before their diagnosis were more likely to have died within ten years of being diagnosed. The significant findings showed that 50% more of these group members had died than those who attended both most recent appointments. Overall, women who attended only one of the two breast cancer screenings had 29% higher mortality than those who attended both. While the research team anticipated a higher mortality rate among women who missed even one mammogram before their diagnosis, the disparity was astounding. As researchers unveil more evidence to highlight the importance of mammograms, however, medical professionals continue to identify a decrease in the number of women who undertake regular screenings. Tragically, the COVID-19 pandemic has also caused a significant decline in the number of women attending their regular mammograms.  What Next? Duffy, Laszlo, and their team hope their recent findings will inspire women to keep up-to-date with their mammogram appointments and plan to continue further prognostic research into the mechanisms of this effect. The team will explore to what extent regular attendance improves the prognosis of interval cancers and screen-detected cancers.  While the world eagerly awaits the following report, women must continue adhering to the current mammogram recommendations. Those with questions regarding their personal situation and recommendations should speak to their general practitioner.  For more information regarding breast cancer, please visit NFCR’s breast cancer page.  Note: The third Friday in October we recognize National Mammography Day. This year it will be celebrated on October 15, 2021. Please take this opportunity to schedule your mammogram or share important information with loved ones. Additional Reads You May Enjoy: Let’s talk about Mammograms with Dr. Alexia Matheson National Mammography Day 5 Ways You Can Show Support for Breast Cancer Patients Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

Controlling the Uncontrollable: HER2 Breast Cancer

It’s that time of year when pink ribbons begin appearing everywhere – from shopfronts to social media. These ribbons are known to be Breast Cancer Awareness ribbons. It’s no coincidence that pink ribbons are the most easily recognized as breast cancer is the most common cancer in women worldwide. In fact, one in eight women will be diagnosed with breast cancer.  Tragically, the likelihood of experiencing metastasis, or cancer that spreads to other parts of the body, is high amongst these patients. Understanding and preventing metastasis is crucial to increasing the survival rates of this disease. Thankfully, National Foundation for Cancer Research (NFCR)-funded researcher Dr. Rakesh K. Jain and his team are dedicated to exploring this phenomenon and recently unearthed a game-changing discovery.  Their mission: HER2 Dr. Jain and his team knew that genes contain the recipes for various proteins required for healthy cells to function properly and that some genes and proteins can influence how breast cancer behaves and responds to treatment. They were particularly interested in exploring how to control and inhibit metastasis in one particular gene related to breast cancer, the HER2 gene.  The HER2 (human epidermal growth factor receptor 2) gene makes HER2 proteins, which are receptors on breast cells. Typically, HER2 receptors help control how a healthy breast cell grows, divides, and repairs itself. But in about 10% to 20% of breast cancers, the HER2 gene doesn’t work correctly and makes too many copies of itself (known as HER2 gene amplification). These extra HER2 genes tell breast cells to make too many HER2 receptors which makes breast cells grow and divide in an uncontrolled way. Patients with metastatic HER2+ breast cancer often experience treatment resistance, disease recurrences, and metastases. Dr. Jain and his team believed that by modifying the tumor framework and increasing oxygenation in the tumor, it might be possible for an existing medication to improve the outcome of radiotherapy and inhibit disease progression in a highly metastatic HER2+ breast cancer. Their findings The team established a metastatic HER2+ breast cancer line and used it to generate a similar environment in mice. Three days after tumor implantation, Dr. Jain and his team administered seven days of Losartan, a drug mainly used to treat high blood pressure. In some mice, the research team followed the seven days of Losartan with 20 Gy single dose local irradiation on day 10. In a third group, they followed the seven days of Losartan with 20 Gy fractionated irradiation on days 10-14. For each group, the researchers analyzed the tumor-growth delay, development of metastases, survival rates, tumor density, and oxygen levels in the tumor.  Much to the excitement of cancer researchers worldwide, the combination of Losartan and local irradiation significantly enhanced tumor response. The tumors were deprived of oxygen, whereas healthy cells remained oxygen-rich. This finding suggests that combining Losartan with radiotherapy is a potential new treatment strategy for controlling and inhibiting metastasis in HER2+ breast cancer – a potentially life-saving discovery. Other exciting HER2 discoveries  HER2 has been a hot topic in the cancer world for years. In fact, Dr. Jain is just one of the NFCR-funded researchers paving the way to better treatment options related to HER2. Dr. […]

Exploring the Mechanisms of Breast Cancer Metastasis: NFCR-Supported Research Update